Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesKey targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase
BJU International, 07/16/09
Vis AN et al. - Achieving more potent suppression of intracellular DHT synthesis by 5AR inhibition is expected to provide clinical benefit to patients. Previous studies have shown that 5AR inhibition, by dutasteride in particular, halts/delays the progression of disease, and might even cause regression of disease in patients with advanced prostate cancer.
Related Articles
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine, 10/30/09
Relevance Score: 68%
Depressive tendency in children with growth hormone deficiency
Journal of Paediatrics and Child Health, 10/23/09
Relevance Score: 68%
Short-term treatment with olanzapine does not modulate gut hormone secretion; olanzapine disintegrating vs standard tablets
European Journal of Endocrinology, 10/14/09
Relevance Score: 68%
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Relevance Score: 67%
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
Annals of Internal Medicine, 10/23/09
Relevance Score: 67%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Patient Perceived Effectiveness of a New Male Sling as Treatment for Post-Prostatectomy Incontinence
The Journal of Urology, 12/18/09
Health-related quality of life in men with localized prostate cancer
International Journal of Urology, 12/18/09
Article Search
Sponsor